Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins

International Journal of Molecular Medicine

Volumn 24, Issue 5, 2009, Pages 633-643

  Perchellet, Jean Pierre H ^a   Perchellet, Elisabeth M ^b   Crow, Kyle R ^a   Buszek, Keith R ^b,c   Brown, Neil ^b,c   Ellappan, Sampathkumar ^b   Gao, Ge ^b   Luo, Diheng ^b   Minatoya, Machiko ^b   Lushington, Gerald H ^c  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

HMG CoA reductase activity; Statin drugs; Synthetic medium ring lactams; Tumor cell proliferation

Indexed keywords

AMINE; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTAM; MEDIUM RING LACTAM; MEVINOLIN; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CATALYSIS; CELL FREE SYSTEM; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; LEUKEMIA L 1210; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIGANDS; MICE; MODELS, MOLECULAR; SPECTROPHOTOMETRY;

EID: 70350768857     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000274     Document Type: Article

References (48)

1. Tapiolas DM, Roman M, Fenical W, Stout TJ and Clardy J: Octalactins A and B: cytotoxic eight-membered-ring lactones from a marine bacterium, Streptomyces sp. J Am Chem Soc 113: 4682-4683, 1991.
2. Perchellet JP, Perchellet EM, Newell SW, Freeman JA, Ladesich JB, Jeong Y, Sato N and Buszek KR: Antitumor activity of novel octalactin A analogs in murine leukemia cells in vitro. Anticancer Res 18: 97-106, 1998.
3. Brown N, Xie B, Markina N, VenderVelde D, Perchellet JP, Perchellet EM, Crow KR and Buszek KR: Synthesis of a natural product-inspired eight-membered ring lactam library via ring-closing metathesis. Bioorg Med Chem Lett 18: 4876-4679, 2008.
4. Brown N, Gao G, Minatoya M, Xie B, VanderVelde D, Lushington GH, Perchellet JP, Perchellet EM, Crow KR and Buszek KR: Design and synthesis of medium-ring lactam libraries inspired by octalactin A. A convergent-divergent approach. J Comb Chem 10: 628-631, 2008.
5. Buszek KR: First intramolecular benzyne Diels-Alder reaction with an acyclic diene. Unusual effect of diene geometry on the course of the reaction. Tetrahedron Lett 36: 9125-9128, 1995.
6. Buszek KR and Bixby DL: Total synthesis of pseudopterosin A and E aglycon. Tetrahedron Lett 36: 9129-9132, 1995.
7. Buszek KR, Luo D, Kondrashov M, Brown N and VanderVelde D: Indole-derived arynes and their Diels-Alder reactivity with furans. Org Lett 9: 4135-4137, 2007.
8. Buszek KR, Brown N and Luo D: Concise total Synthesis of (±)-cis-trikentrin A and (±)-herbindole A via intermolecular indole aryne cycloaddition. Org Lett 11: 201-204, 2009.
9. Brown N, Luo D, VanderVelde D, Yang S, Brassfield A and Buszek KR: Regioselective Diels- Alder cycloadditions and other reactions of 4,5-, 5,6-, and 6,7-indole arynes. Tetrahedron Lett 50: 63-65, 2009.
10. Hayes ME, Shinokubo H and Danheiser RL: Intramolecular [4+2] cycloadditions of benzynes with conjugated enynes, arenynes, and dienes. Org Lett 7: 3917-3920, 2005.
11. Cory AH, Owen JC, Barltrop JA and Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212, 1991.
12. Park WKC, Kennedy RM, Larsen SD, Miller S, Roth BD, Song Y, Steinbaugh BA, Sun K, Tait BD, Kowala MC, Trivedi BK, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu GH, Robertson A and Sekerke C: Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Bioorg Med Chem Lett 18: 1151-1156, 2008.
13. UNITY 4.4.3 (2007): The Tripos Associates, St. Louis MO, 2007.
14. SYBYL 8.0 (2007): The Tripos Associates, St. Louis MO, 2007.
15. Istvan ES and Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-1164, 2001.
16. Istvan ES, Palnitkar M, Buchanan SK and Deisenhofer J: Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and analysis. EMBO J 19: 819- 830, 2000.
17. Sarver RW, Bills E, Bolton G, Bratton LD, Caspers NL, Dunbar JB, Harris MS, Hutchings RH, Kennedy RM, Larsen SD, Pavlovsky A, Pfefferkorn JA and Bainbridge G: Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase. J Med Chem 51: 3804-3813, 2008.
18. Jain AN: Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46: 499-511, 2003.
19. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
20. Demierre MF, Higgins PDR, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005.
21. Hawk E and Viner JL: Statins and cancer-beyond the 'one drug, one disease' model. N Engl J Med 352: 2238-2239, 2005.
22. Paraskevas KI, Tzovaras AA, Briana DD and Mikhailidis DP: Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 13: 3622-3636, 2007.
23. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002.
24. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003.
25. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641, 2004.
26. Fritz G: HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review). Int J Oncol 27: 1401-1409, 2005.
27. Holdgate GA, Ward WHJ and McTaggart F: Molecular mechanism for inhibition of 3-hydroxy-3- methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31: 528-531, 2003.
28. Friesen JA and Rodwell VW: The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 5: 248, Epub Nov 1, 2004.
29. Istvan ES and Deisenhofer J: The structure of the catalytic portion of human HMG-CoA reductase. Biochim Biophys Acta 1529: 9-18, 2000.
30. Endo A, Kuroda M and Tanzawa K: Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72: 323-326, 1976.
31. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J and Springer J: Mevinolin: a highly potent competitive inhibitor of hydroxy-methylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957-3961, 1980.
32. Louis-Flamberg P, Peishoff CE, Bryan DL, Leber J, Elliott JD, Metcalf BW and Mayer RJ: Slow binding inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Biochemistry 29: 4115- 4120, 1990.
33. Repko EM and Maltese WA: Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability. J Biol Chem 264: 9945-9952, 1989.
34. Casey PJ, Solski PA, Der CJ and Buss JE: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323-8327, 1989.
35. Maltese WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4: 3319-3328, 1990.
36. Sinensky M: Recent advances in the study of prenylated proteins. Biochim Biophys Acta 1484: 93-106, 2000.
37. Siperstein MD: Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 25: 1462-1468, 1984.
38. Caruso MG and Notarnicola M: Biochemical changes of mevalonate pathway in human colorectal cancer. Anticancer Res 25: 3393-3398, 2005.
39. Rudling MJ, Angelin B, Peterson CO and Collins VP: Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 50: 483-487, 1990.
40. Bennis F, Favre G, Le Gaillard F and Soula G: Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55: 640-645, 1993.
41. Hentosh P, Yuh SH, Elson CE and Peffley DM: Sterol-independent regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 32: 154-166, 2001.
42. Notarnicola M, Messa C, Pricci M, Guerra V, Altomare DF, Montemurro S and Caruso MG: Up- regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res 24: 3837-3842, 2004.
43. Schafer WR, Kim R, Sterne R, Thorner J, Kim SH and Rine J: Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245: 379-385, 1989.
44. Jakobisiak M, Bruno S, Skierski JS and Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632, 1991.
45. Keyomarsi K, Sandoval L, Band V and Pardee AB: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991.
46. Gray-Bablin J, Rao S and Keyomarsi K: Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57: 604-609, 1997.
47. Lee SJ, Ha MJ, Lee J, Nguyen PM, Choi YH, Pirnia F, Kang W-K, Wang X-F, Kim S-J and Trepel JB: Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21WAF1/CIP1 in human prostate carcinoma cells. J Biol Chem 273: 10618-10623, 1998.
48. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG and Holt PR: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5: 2223- 2229, 1999.